Rhenman & Partners Asset Management Ab Relay Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 460,000 shares of RLAY stock, worth $1.95 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
460,000
Previous 230,000
100.0%
Holding current value
$1.95 Million
Previous $1.5 Million
117.21%
% of portfolio
0.27%
Previous 0.15%
Shares
5 transactions
Others Institutions Holding RLAY
# of Institutions
204Shares Held
156MCall Options Held
207KPut Options Held
40K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$118 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.5MShares$61.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$44.6 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY9.25MShares$39.1 Million5.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.38MShares$31.2 Million0.88% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $509M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...